Search Results - "Gaballa, Mahmoud R."

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia by Gaballa, Mahmoud R., Banerjee, Pinaki, Milton, Denái R., Jiang, Xianli, Ganesh, Christina, Khazal, Sajad, Nandivada, Vandana, Islam, Sanjida, Kaplan, Mecit, Daher, May, Basar, Rafet, Alousi, Amin, Mehta, Rohtesh, Alatrash, Gheath, Khouri, Issa, Oran, Betul, Marin, David, Popat, Uday, Olson, Amanda, Tewari, Priti, Jain, Nitin, Jabbour, Elias, Ravandi, Farhad, Kantarjian, Hagop, Chen, Ken, Champlin, Richard, Shpall, Elizabeth, Rezvani, Katayoun, Kebriaei, Partow

“…Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted…”
Get full text

High antigen density of BCMA: friend or foe to CAR T cells? by Gaballa, Mahmoud R, Maus, Marcela V

“…The therapeutic landscape of multiple myeloma (MM) has been rapidly evolving with the development of newer modalities such as chimeric antigen receptor T-cell…”
Get full text

Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies by Singh, Harjeet, Srour, Samer A, Milton, Denái R, McCarty, Jessica, Dai, Cuiping, Gaballa, Mahmoud R, Ammari, Mariam, Olivares, Simon, Huls, Helen, De Groot, Eleanor, Marin, David, Petropoulos, Demetrios, Olson, Amanda L, Anderlini, Paolo, Im, Jin S, Khouri, Issa, Hosing, Chitra M, Rezvani, Katayoun, Champlin, Richard E, Shpall, Elizabeth J, Cooper, Laurence J N, Kebriaei, Partow

“…Chimeric antigen receptor (CAR) T-cell therapy has emerged recently as a standard of care treatment for patients with relapsed or refractory acute…”
Get full text

Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy by Johnson, P Connor, Jacobson, Caron, Yi, Alisha, Gaballa, Mahmoud R, Horick, Nora, Rabideau, Dustin J, Lindell, Kevin, DePinho, Gabriel D, El-Jawahri, Areej R, Frigault, Matthew J

“…BackgroundChimeric antigen receptor (CAR) T-cell therapy recipients may receive bridging therapy while awaiting product manufacturing to control disease. Yet,…”
Get full text

Acute Lymphoblastic Leukemia Presenting Initially as Spinal Cord Compression: When Chemotherapy Alone Is Enough by Miller-Chism, Courtney N., Lu, Lee B., Gaballa, Mahmoud R., Berger, Scott N., Kram, Kallie N., Jang, Albert, Dunaway, David R.

“…Spinal cord compression (SCC) is a rare initial presentation and complication of acute lymphoblastic leukemia (ALL) with nearly all reported cases occurring in…”
Get full text

Diabesity: an overview of a rising epidemic by Farag, Youssef M K, Gaballa, Mahmoud R

“…'Diabesity' is the term for diabetes occurring in the context of obesity. In this review, we will overview the latest epidemiological data available describing…”
Get full text

Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T‐cell therapy by Dhawale, Tejaswini M., Johnson, P. Connor, Gaballa, Mahmoud R., Nelson, Ashley M., Lavoie, Mitchell W., Boateng, Kofi Y., Greydanus, Claire, Frigault, Matthew J., El‐Jawahri, Areej

“…Background Chimeric antigen receptor (CAR) T‐cell is potentially curative therapy for patients with hematologic malignancies but can cause life‐threatening…”
Get full text

Management of myeloma-associated renal dysfunction in the era of novel therapies by Gaballa, Mahmoud R, Laubach, Jacob P, Schlossman, Robert L, Redman, Katherine, Noonan, Kimberly, Mitsiades, Constantine S, Ghobrial, Irene M, Munshi, Nikhil, Anderson, Kenneth C, Richardson, Paul G

“…Multiple myeloma (MM) is a plasma cell neoplasm often associated with renal impairment (RI), with myeloma cast nephropathy recognized as the most common cause…”
Get more information

Cellular Immunotherapy in Lymphoma: Beyond CART Cells by Gaballa, Mahmoud R., Ramos, Carlos A.

“…Opinion statement Cellular immunotherapy has been rapidly evolving and increasingly utilized in the management of relapsed and refractory lymphoma…”
Get full text

KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma by Gaballa, Mahmoud R., Ma, Junsheng, Rauf, Mikael, Bassett, Roland, Pasvolsky, Oren, Tanner, Mark R., Bashir, Qaiser, Srour, Samer A., Saini, Neeraj, Ramdial, Jeremy, Nieto, Yago, Murphy, Regan, Rezvani, Katayoun, Tang, Guilin, Lin, Pei, Lee, Hans C., Patel, Krina K., Ullah, Muhammad R., Kaufman, Gregory P., Manasanch, Elisabet E., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Shpall, Elizabeth J., Champlin, Richard E., Orlowski, Robert Z., Qazilbash, Muzaffar H.

“…Bortezomib, lenalidomide, and dexamethasone (VRD) induction is standard prior to autologous hematopoietic cell transplantation (auto-HCT) in newly diagnosed,…”
Get full text

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide by Gaballa, Mahmoud R., Besa, Emmanuel C.

“…Myelodysplastic syndrome (MDS) is a hematopoietic stem cell disorder primarily affecting CD34+ cells, characterized by ineffective hematopoiesis, often…”
Get full text

Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance by Gaballa, Mahmoud R., Ma, Junsheng, Tanner, Mark R., Al-Juhaishi, Taha, Bashir, Qaiser, Srour, Samer A., Saini, Neeraj Y., Ramdial, Jeremy L., Nieto, Yago, Murphy, Regan, Rezvani, Katayoun, Tang, Guilin, Lee, Hans C., Patel, Krina K., Kaufman, Gregory P., Manasanch, Elisabet E., Ullah, Muhammad R., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., Qazilbash, Muzaffar H.

“…Standard-of-care for newly-diagnosed, autologous hematopoietic stem cell transplantation (auto-HCT)-eligible, multiple myeloma (MM) patients includes…”
Get full text

Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades by Pasvolsky, Oren, Marcoux, Curtis, Dai, Jianliang, Milton, Denái R., Tanner, Mark R., Syed, Naureen, Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Tang, Guilin, Aljawai, Yosra, Lee, Hans C., Gaballa, Mahmoud R, Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., Qazilbash, Muzaffar H.

“…•Retrospective study of NDMM patient outcomes following auto-SCT from 1988-2021.•Average age and comorbidity burden of transplanted patients increased over…”
Get full text

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience by Pasvolsky, Oren, Gaballa, Mahmoud R., Milton, Denái R., Masood, Adeel, Sami, Sophiya S., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Ramdial, Jeremy, Nieto, Yago, Tang, Guilin, Lin, Pei, Lee, Hans C., Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., Qazilbash, Muzaffar H.

“…•Outcomes of patients with t(4;14) multiple myeloma remain poor despite novel agent induction, autologous hematopoietic stem cell transplantation (auto-HCT)…”
Get full text

Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer by Oran, Amanda R, Adams, Clare M, Zhang, Xiao-Yong, Gennaro, Victoria J, Pfeiffer, Harla K, Mellert, Hestia S, Seidel, Hans E, Mascioli, Kirsten, Kaplan, Jordan, Gaballa, Mahmoud R, Shen, Chen, Rigoutsos, Isidore, King, Michael P, Cotney, Justin L, Arnold, Jamie J, Sharma, Suresh D, Martinez-Outschoorn, Ubaldo E, Vakoc, Christopher R, Chodosh, Lewis A, Thompson, James E, Bradner, James E, Cameron, Craig E, Shadel, Gerald S, Eischen, Christine M, McMahon, Steven B

“…Despite ubiquitous activation in human cancer, essential downstream effector pathways of the MYC transcription factor have been difficult to define and target…”
Get full text

Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia by Alattar, Mona Lisa, Ciccone, Maria, Gaballa, Mahmoud R., Vitale, Candida, Badoux, Xavier C., Manoukian, George, Keating, Michael J., Kroll, Michael H., Ferrajoli, Alessandra

Get full text

Predictors of diabetic nephropathy by Gaballa, Mahmoud R., Farag, Youssef M. K.

“…Diabetic nephropathy (DN) is a leading cause of morbidity and mortality in diabetic patients representing a huge health and economic burden. Alarming recent…”
Get full text

Advances in Cellular Immunotherapy in Hematologic Malignancies by Gaballa, Mahmoud R., Kebriaei, Partow

Get full text

Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy by Dhawale, Tejaswini, Johnson, P. Connor, Gaballa, Mahmoud R., Nelson, Ashley, Lavoie, Mitchell W., Frigault, Matthew, Boateng, Kofi, Greydanus, Claire, El-Jawahri, Areej

Get full text

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma by Frigault, Matthew, Rosenblatt, Jacalyn, Dhakal, Binod, Raje, Noopur, Cook, Daniella, Gaballa, Mahmoud R., Emmanuel-Alejandro, Estelle, Nissen, Danielle, Cornwell, Christine, Banerjee, Kamalika, Rotte, Anand, Heery, Christopher R., Avigan, David, Jakubowiak, Andrzej, Bishop, Michael R.

Get full text